Clément Beaulaton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Clément Beaulaton has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Alice Durand
Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'oncologie médicale, Lyon, France
1 shared publication - Andrei Zinovyev
Evotec SE, Hamburg, Germany
1 shared publication Arnaud Jannin
Département d'Endocrinologie, CHU de Lille, Lille, F-59000, France
1 shared publicationAude Marchal
Service d'anatomo-pathologie, CHU Reims, Reims, France
1 shared publicationCaroline Petorin
CHU Clermont-Ferrand, Service de Chirurgie Digestive et Hépatobiliaire, 1 rue Lucie et Raymond Aubrac, F-63003, Clermont-Ferrand, France
1 shared publication- Christina Kanaan
Department of Pathology and Laboratory Medicine, Gustave Roussy and Paris Saclay University, 114 Rue Edouard Vaillant, 94800, Villejuif, France.
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 12 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Integration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancer
Immunotherapy is improving the survival of patients with metastatic non-small cell lung cancer (NSCLC), yet reliable biomarkers are needed to identify responders prospectively and optimize patient care. In this study, we explore the benefits of multimodal approaches to predict immunotherapy outcome using multiple machine learning algorithms and integration strategies. We analyze baseline multimodal data from a cohort of 317 metastatic NSCLC patients treated with first-line immunotherapy, including positron emission tomography images, digitized pathological slides, bulk transcriptomic profiles, and clinical information. Testing multiple integration strategies, most of them yield multimodal models surpassing both the best unimodal models and established univariate biomarkers, such as PD-L1 expression. Additionally, several multimodal combinations demonstrate improved patient risk stratification compared to models built with routine clinical features only. Our study thus provides evidence of the superiority of multimodal over unimodal approaches, advocating for the collection of large multimodal NSCLC datasets to develop and validate robust and powerful immunotherapy biomarkers.
- 12 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Top Cited PapersOpen AccessIntegration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancer
Immunotherapy is improving the survival of patients with metastatic non-small cell lung cancer (NSCLC), yet reliable biomarkers are needed to identify responders prospectively and optimize patient care. In this study, we explore the benefits of multimodal approaches to predict immunotherapy outcome using multiple machine learning algorithms and integration strategies. We analyze baseline multimodal data from a cohort of 317 metastatic NSCLC patients treated with first-line immunotherapy, including positron emission tomography images, digitized pathological slides, bulk transcriptomic profiles, and clinical information. Testing multiple integration strategies, most of them yield multimodal models surpassing both the best unimodal models and established univariate biomarkers, such as PD-L1 expression. Additionally, several multimodal combinations demonstrate improved patient risk stratification compared to models built with routine clinical features only. Our study thus provides evidence of the superiority of multimodal over unimodal approaches, advocating for the collection of large multimodal NSCLC datasets to develop and validate robust and powerful immunotherapy biomarkers.
- 1 July 2021
- Published by Elsevier in European Journal of Cancer
- Vol. 152, 100-115
Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d’Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network
- 1 July 2021
- Published by Elsevier in European Journal of Cancer
- Vol. 152, 100-115
Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d’Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network